ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non-Small-Cell Lung Cancer.

Overview of attention for article published in Journal of Clinical Oncology, March 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (88th percentile)

So far, Altmetric has seen 3 public wall posts from 3 users.

PURPOSE Lorlatinib is a potent, brain-penetrant, third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase…

JTO Research Watch: "ALK Resistance Mutations and Efficacy of Lorlatinib in Advanced Anaplastic Lymphoma Kinase-Positive Non–Smal…

La tipizzazione genetica del tumore per le mutazioni ALK, dopo fallimento di un TKI di seconda generazione (dunque escluso il…

This page shows the most recent Facebook posts that mention this research output.

Click here to find out how to access more activity.